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Coronary stents reduce the rates of abrupt closure, emergency coronary artery bypass graft
surgery and restenosis, but do not prevent myocardial infarction or death at six months. The
financial burden of increased stent use and the difficulty in managing in-stent restenosis have
provided the impetus to develop provisional stenting strategies. Patients at low risk for
restenosis after balloon angioplasty may not derive additional benefit from stent implantation
and may be successfully managed with percutaneous transluminal coronary angioplasty
(PTCA) alone. Numerous patient, lesion and procedural predictors of restenosis have been
identified. Postprocedural assessment using quantitative coronary angiography, intravascular
ultrasound (IVUS), coronary flow velocity reserve (CVR) or fractional flow reserve (FFR) may
further enhance the ability to predict adverse outcomes after PTCA. Several studies have been
performed to investigate the feasibility of provisional stenting strategies using various
modalities to identify low risk patients who could be managed with PTCA alone. An optimal
or “stent-like” angiographic result after PTCA is associated with favorable clinical outcomes.
Preliminary results of studies using IVUS or CVR to guide provisional stenting appear
promising. Angiography alone may be inadequate to identify truly low risk patients and may
need to be combined with clinical factors, assessment of recoil, IVUS or physiologic indexes.
Strategies that avoid unnecessary stenting in even a small proportion of patients may have
large impacts on health care costs. Provisional stenting may potentially reduce costs and rates
of in-stent restenosis without compromising the quality of health care delivery. (J Am Coll
Cardiol 2000;36:1142–51) © 2000 by the American College of Cardiology
As health care costs continue to rise, physicians are increas-
ingly being called on to practice cost-effective, evidence-
based medicine. The struggle to maintain the quality of
health care in the face of increasing financial pressures has
surfaced in the field of interventional cardiology. Specifi-
cally, although coronary stents improve procedural out-
comes, they also add significant cost to the initial procedure,
which is offset by a later reduction in repeat procedures
(1,2). However, this later financial benefit is frequently not
realized by the hospital; instead, the cost of the initial
procedure is usually carried by the hospital, which does not
receive higher reimbursement for procedures that could
provide lower long-term costs. Stents are being used for an
increasingly broad population of patients. The high cost to
hospitals created by increased stent use has prompted a
reevaluation of the indications for stenting (3,4). This report
will briefly review the known benefits and limitations of
stents, discuss the concept of provisional stenting and its
cost implications and present various strategies for provi-
sional stenting and the results of recently completed studies.
BENEFITS AND LIMITATIONS OF STENT USE
Benefits. Stents lower the rates of abrupt closure, emer-
gency coronary artery bypass graft surgery and restenosis
(5–10). Two large multicenter trials—the STent RESteno-
sis Study (STRESS) (9) and the BElgium NEtherlands
STENT (BENESTENT) study (10)—compared elective
stenting with angioplasty alone in native coronary arteries
with short (,15 mm in length) de novo lesions and showed
a 25% to 30% reduction in restenosis. Later stent trials
confirmed reduced rates of restenosis and target lesion
revascularization (TLR) (10–21) (Table 1). The STRESS
and BENESTENT results led to a marked enthusiasm for
stent use and a dramatic rise in the number of stent
procedures performed worldwide (22). For example, stent
use in 12 U.S. centers rose 12-fold from 1994 to 1997 (from
5.4% to 69%) (23). Although stenting carries reduced rates
of restenosis and abrupt closure, a recent meta-analysis of
stent trials found no reduction in the rates of myocardial
infarction (MI) or death during six-month follow-up (24).
A recent analysis of a large Canadian data base has also
confirmed that the major clinical benefit conferred by
stenting is a reduction in repeat revascularization procedures
(25).
Limitations. The use of stents is not without limitations
and complications. Stent thrombosis occurs in ,1% of
cases, but may result in MI, urgent TLR and death. Stent
implantation achieves larger lumen dimensions and prevents
early recoil, but stimulates neointimal proliferation, result-
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ing in higher rates of late lumen loss, as compared with
angioplasty alone. Restenosis rates after stent implantation
range from ,10% to 58%, depending on lesion, stent,
patient and procedural characteristics, definitions and an-
giographic surveillance (26,27). Diffuse in-stent restenosis
appears to be much more difficult to manage than restenosis
after percutaneous transluminal coronary angioplasty
(PTCA) (26,28). Treatment strategies for in-stent resten-
osis (PTCA, atheroablation or additional stent implanta-
tion) are associated with high recurrence rates (29). How-
ever, intracoronary radiation therapy is a promising new
investigational approach to treat in-stent restenosis (30).
Generalizability of clinical trial results. The initial
STRESS and BENESTENT trials enrolled highly selected
subjects with favorable patient and lesion characteristics.
Less than 30% of patients undergoing stenting in current
clinical practice would have been eligible for these trials
(31–34). It is not surprising, therefore, that clinical out-
comes in “real-world” stenting have not been as consistent
as those seen in randomized studies (31–35). More recent
trials have extended the findings of STRESS and
BENESTENT to vein graft lesions (17), total occlusions
(19,20), restenotic lesions (16) and acute MI (36). However,
the results of stenting in small vessels, diffuse disease and
bifurcations remain unsatisfactory, and the benefit of stents
over balloon angioplasty in these lesion types has not been
clearly established (37,38).
Newer stent designs and deployment techniques. Since
the time of the STRESS and BENESTENT studies,
considerable advances have been made in the design of
stents and in the techniques used to deploy them. Second-
and third-generation stent designs have improved flexibility
and lower profiles, facilitating their delivery. Optimal stent
expansion, achieved with the use of high pressure inflations
or intravascular ultrasound (IVUS), or both, results in larger
postprocedural lumen areas and lower rates of subacute stent
thrombosis (39). However, the impact of these advances on
restenosis rates is unclear. Table 2 lists the restenosis and
TLR rates observed in studies of modern stent designs and
deployment techniques (40–47). The Multicenter Ultra-
sound Stenting in Coronaries (MUSIC) study used IVUS
to optimize stent expansion in low risk patients and ob-
served remarkably low TLR and restenosis rates of 4.5% and
8.3%, respectively. The restenosis rates in two other trials of
IVUS-guided stent implantation ranged from 23% to 25%
(48,49). The MUlticenter STent (MUST) registry evalu-
ated stenting using high pressure inflations without IVUS
guidance and observed a low TLR rate of 6%. In contrast,
the STRESS-3 registry found no significant difference in
six-month restenosis rates (31.4% vs. 31.6%) (3) or one-year
TLR rates (8.3% vs. 12.2%, p 5 0.2) (42), as compared with
the stent arm of the first STRESS study. A recent random-
ized trial showed no difference in restenosis rates with high
pressure inflations during stent deployment (50). High
pressure inflations can cause increased arterial wall trauma,
which may accelerate intimal hyperplasia and offset the
larger lumen area initially achieved. Randomized trials
comparing newer stents with Palmaz-Schatz stents have
Abbreviations and Acronyms
CVR 5 coronary flow velocity reserve
FFR 5 fractional flow reserve
IVUS 5 intravascular ultrasound
LAD 5 left anterior descending coronary artery
MI 5 myocardial infarction
MLD 5 minimum lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
QCA 5 quantitative coronary angiography
TLR 5 target lesion revascularization
Table 1. Randomized Trials of Stenting Versus Balloon Angioplasty
Study Indication n
Angiographic Restenosis
Target Vessel
Revascularization
Stent
Group
PTCA
Group
p
Value
Stent
Group
PTCA
Group
p
Value
STRESS-I 1 II (11) Discrete, de novo lesions 596 30% 45% 0.0001 10% 18% 0.003
BENESTENT (10) Discrete, de novo lesions 520 22% 32% 0.02 14%* 23%* 0.005
BENESTENT-II (12) Discrete, de novo lesions 827 16% 31% 0.0008 5%† 12%† 0.001
START (13) Discrete, de novo lesions 452 22% 37% 0.001 9% 19% , 0.01
TASC-1 (14,15) De novo and restenotic lesions 270 31% 46% 0.01 4% 10% 0.08
REST (16) Restenotic lesions 383 18% 32% 0.03 10% 27% 0.001
SAVED (17) Saphenous vein grafts 220 37% 46% 0.24 17% 26% 0.09
Versaci et al. (18) LAD lesions 120 19% 40% 0.02 7% 23% 0.01
SICCO (19) Chronic occlusions 119 32% 74% ,0.001 22% 42% 0.03
TOSCA (20) Chronic occlusions 410 55% 70% ,0.01 8% 15% 0.03
EPISTENT (21)‡ Wide range 1590 NA NA NA 9% 15% 0.001
Total 5507 28% 43% 0.001 9% 18% 0.001
*Repeat PTCA only, does not include bypass surgery. †For patients assigned to clinical follow-up only (n 5 411). ‡For the two abciximab groups only.
BENESTENT 5 BElgian NEtherlands STENT study; EPISTENT 5 Evaluation of Platelet glycoprotein IIb/IIIa inhibitor for STENTing; LAD 5 left anterior descending
coronary artery; NA 5 not available; PTCA 5 percutaneous transluminal coronary angioplasty; REST 5 REstenosis STent study; SAVED 5 SAphenous VEin De novo trial;
SICCO 5 Stenting in Chronic Coronary Occlusion; START 5 Stent Versus Angioplasty Restenosis Trial; STRESS 5 STent REStenosis Study; TASC 5 Trial of Angioplasty
and Stents in Canada; TOSCA 5 Total Occlusion Study of CAnada.
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found similar restenosis rates, with the exception of the
GR-II stent (47). However, these small studies may not
have been adequately powered to detect subtle differences in
clinical and angiographic outcomes (51). In summary,
modern stent designs and deployment techniques have
likely improved procedural success rates and lowered the
risk of subacute stent thrombosis. However, the effect of
stent design, IVUS and high pressure inflations on resten-
osis rates remains unclear.
Cost implications. Stent implantation greatly increases the
cost of PTCA. Early observational studies estimated that
stenting increased in-hospital costs by 50% to 100% (52,53).
In randomized trials, these excess costs were only partially
recovered by the lower rate of repeat procedures for patients
receiving stents during follow-up (1,54). Using data from
the 1994 STRESS study, Cohen et al. (1) estimated a
one-year net excess cost of $1,200 (U.S.) per patient for
stenting as compared with PTCA alone.
Advances in stent deployment techniques and adjuvant
pharmacotherapy have eliminated the need for intense oral
anticoagulation after stenting, resulting in fewer bleeding
complications and shorter hospital stays (39,55). Despite
these improvements, the cost of stent procedures at one
center increased over time (56), due to increased numbers of
balloon catheters and stents used per patient. Another
institution documented declining costs despite increased
equipment use (57). In the BENESTENT-II study, which
used modern stent deployment techniques and antiplatelet
regimens, the average cost of stent procedures was approx-
imately $1,300 more than that of PTCA procedures (12).
An economic analysis of the Evaluation of Platelet glyco-
protein IIb/IIIa inhibitor for STENTing (EPISTENT)
study showed that the use of stents and abciximab was
cost-effective, with a favorable cost-effectiveness ratio of
$5,291 per added life-year for stents plus abciximab as
compared with balloon angioplasty plus abciximab (58).
Nevertheless, a strategy of provisional stenting with clinical
outcomes similar to those of elective stenting would be even
more cost-effective.
A recent analysis from Duke University found that the
in-hospital costs for stent procedures were $3,268 more per
patient than the costs for PTCA alone (2). Because there are
an estimated 500,000 stent procedures performed in the
U.S. in 1998 (59), a strategy that could eliminate the use of
stenting in even 10% of procedures could save over $160
million per year. If the use of stents could be reduced by
50%, the savings would exceed $800 million per year. The
implicit assumption in these calculations is that clinical
outcomes with these strategies are equivalent to those seen
with elective stenting. Otherwise, the initial cost savings
may be offset by the costs of additional repeat revascular-
ization procedures (2).
PROVISIONAL STENTING—PATIENT IDENTIFICATION
The primary benefit of stents after successful angioplasty is
the reduction in clinical and angiographic restenosis. Given
that ,20% of patients undergoing angioplasty alone require
TLR (12), many patients with successful angioplasty prob-
ably do not gain any additional clinical benefit from stent-
ing. When stent use is reserved for patients most likely to
benefit, it is referred to as “provisional stenting,” in contrast
to “elective” or “obligatory” stenting, in which all technically
eligible patients receive a stent. Many provisional stenting
strategies have been proposed, using a variety of assessment
techniques. Patient, lesion and procedural characteristics
can be used to predict the risk of restenosis (Table 3)
(60–62). In addition, IVUS (63,64) and physiologic flow
and pressure measurements (65,66) are predictive of adverse
outcomes. These predictors can be used individually or
together to identify patients who would have excellent
clinical outcomes with PTCA alone and would be unlikely
to derive further benefit from stent implantation. Provi-
sional stenting could deliver clinical outcomes equivalent to
those with elective stenting, but with substantially reduced
costs and rates of in-stent restenosis.
Baseline clinical and angiographic characteristics. Sev-
eral baseline patient and lesion characteristics are associated
with higher rates of restenosis (Table 3) (60–62). These
predictors may assist in selecting the patients at highest risk
for restenosis and thus most likely to benefit from stent
insertion. Stenting reduces restenosis rates for high risk
Table 2. Studies of Newer Stent Designs and Stent Deployment Techniques
Stent Type Study
Study
Design n
Target Lesion
Revascularization
Angiographic
Follow-Up
Angiographic
Restenosis
Palmaz-Schatz MUST (40) Registry 260 6.2% — —
MUSIC (41) Registry 161 4.5% 92% 8.3%
STRESS III (42) Registry 250 8.3%* NA 31%
ACS Multi-link ASCENT (43) RCT 520 7.5% 60% 15.6%
NIR NIRVANA (44) RCT 420 7.4% 70% 20.0%
FINESS (45) Registry 255 11.9% — —
AVE Micro Stent II SMART (46,47) RCT 330 8.4% NA 25%
Cook GR-II GR-II (46,47) RCT 27%* 75%† 45%
*Rate applies to one-year follow-up. †Follow-up angiography obtained in 75% of first 300 consecutive patients.
ASCENT 5 ACS Multi-Link™ Stent Clinical Equivalence in de novo Lesions Trial; FINESS 5 First International New intravascular rigid-flex Endovascular Stent Study;
GR-II 5 Gianturco-Roubin-II; MUSIC 5 Multicenter Ultrasound Stenting in Coronaries study; MUST 5 Multicenter Stent; NIRVANA 5 Medinol NIR primo stent
Vascular Advances North America Trial; RCT 5 randomized controlled trial; SMART 5 Study of AVE-Micro Stent Ability to Limit Restenosis Trial; other abbreviations as
in Table 1.
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groups, such as patients with proximal left anterior descend-
ing coronary artery (LAD) lesions (18), vein graft interven-
tions (17) and chronic total occlusions (19) (Table 1). In
contrast, stents may not improve outcomes in low risk
groups, such as the non-LAD subgroup of the STRESS
trial (67). In the BENESTENT-2 study, stenting had the
greatest benefit and was most cost-effective in patients with
unstable angina, LAD lesions or vessel size .3 mm (68).
The utility of baseline characteristics to guide stent use has
not been prospectively studied.
Postprocedural angiographic factors. Several postproce-
dural variables are associated with increased risk of resten-
osis after PTCA (61). These variables are listed in Table 3
(60). Multivariate models combining preprocedural and
postprocedural angiographic factors for predicting restenosis
have been developed, albeit with modest predictive strength
(c-index of 0.67) (61). Postprocedural angiographic factors
may help to predict which patients are most likely to benefit
from stent insertion.
EARLY LUMEN LOSS. Early lumen loss, presumably due to
elastic recoil, is an angiographic predictor of restenosis (69).
Two randomized pilot trials have compared elective stenting
with provisional stenting based on assessment of recoil 20 to
30 min after successful PTCA (Table 4) (70,71). In the
Optimal Coronary Balloon Angioplasty with provisional
Stenting (OCBAS) study (70), patients were randomized to
elective stenting or to angioplasty with stenting only for
early lumen loss. Importantly, 86 (42%) of the 206 eligible
patients were excluded owing to suboptimal results or acute
complications. Patients were enrolled only if the final
diameter stenosis was #30% by on-line quantitative coro-
nary angiography (QCA) and no major dissections were
present. Only eight of the 59 patients assigned to PTCA
required stenting for early loss. The patients who had
elective stenting had better early angiographic results, but
clinical and angiographic outcomes did not differ signifi-
cantly at six months. The Balloon Optimization vs. Stent
Study (BOSS) also found similar rates of TLR in the stent
and angioplasty groups (71). These studies, although small,
suggest that assessment of recoil can identify patients who
might benefit from stenting, despite their optimal angio-
plasty results. Unfortunately, the additional 20 to 30 min of
procedure time may be impractical in many catheterization
laboratories and may limit acceptance of this technique.
FINAL MINIMAL LUMEN DIAMETER (MLD). Kuntz et al. (72)
popularized the “bigger is better” paradigm of restenosis by
showing the relation between postprocedural MLD and the
risk of restenosis. The MLD immediately after PTCA
strongly correlated with the MLD at six-month follow-up.
This implies that when a large lumen can be achieved with
PTCA, the low risk of restenosis may obviate the need for
stenting.
FINAL DIAMETER STENOSIS. It has generally been assumed
that patients with suboptimal PTCA results (high residual
diameter stenosis) derive greater benefit from stent implan-
tation than do patients with optimal PTCA results. This
premise is supported by the results of a randomized trial in
which stenting for patients with suboptimal results (residual
stenosis $15%) reduced restenosis from 53% to 24% (p 5
0.02) (73). Patients with optimal results were not random-
ized but were treated with balloon angioplasty and had a low
Table 3. Patient-, Lesion- and Procedure-Related Predictors of Restenosis
Patient Factors Lesion Factors Procedural Factors
Age Bypass graft Postprocedural percent stenosis
Male gender LAD location Postprocedural MLD
Diabetes mellitus Preprocedural percent stenosis Final gradient .15 mm
Hypertension Preprocedural MLD Increased relative gain
High cholesterol Arterial diameter Lack of dissection
Current smoking Lesion length Number of sites dilated
No previous myocardial infarction Total occlusion Duration of inflation
Angina class/severity Calcification Increased stretch
Unstable angina Eccentric lesion Lower balloon/artery ratio
Shorter duration of angina Elastic recoil
Multivessel disease
End-stage renal disease
Adapted from Miller et al. (61), with permission.
LAD 5 left anterior descending coronary artery; MLD 5 minimal lumen diameter.
Table 4. Studies Using Early Lumen Loss Criteria
Study n Criteria for Crossover to Stenting Crossover Restenosis
Target Lesion
Revascularization
OCBAS (70) 116 MLD loss .0.3 mm or .10% increase in
diameter stenosis at 30 min
14% 16% 18%
BOSS (71) 97 MLD loss .0.3 mm at 20 min 36% 38% 21%
BOSS 5 Balloon Optimization vs. Stent Study; MLD 5 minimal lumen diameter; NA 5 not available; OCBAS 5 Optimal Coronary Balloon Angioplasty with provisional
Stenting study.
1145JACC Vol. 36, No. 4, 2000 Cantor et al.
October 2000:1142–51 Strategies for Provisional Stenting
restenosis rate of 14%. Several studies have assessed out-
comes for patients with optimal, or “stent-like,” PTCA
results on the basis of low residual diameter stenosis after
the procedure (Table 5) (21,74–80). The BENESTENT
investigators compared patients with “stent-like” results
after PTCA (defined as a final residual diameter stenosis
#30% with no major dissection) with patients assigned to
elective stenting (74). Of the 255 patients in the PTCA arm
of the trial, 90 (35%) met these criteria. The rates of death,
MI and repeat revascularization at six months in these
patients were similar to those in the stented patients. The
angiographic restenosis rate was 16% in the stent-like
PTCA group, as compared with 22% in the stent group
(p 5 0.3). These findings have been confirmed in subgroup
analyses of the REstenosis STent (REST) study and the
Total Occlusion Study of CAnada (TOSCA) (16,76). The
National Heart, Lung and Blood Institute (NHLBI) PTCA
Registry investigators reported long-term outcomes in pa-
tients with stent-like results, defined as a final diameter
stenosis by visual assessment of #10% (79). Stent-like
results were achieved in 225 (11%) of the 1,989 patients
who had successful PTCA. At 10-year follow-up, the rate
of TLR was significantly lower for patients with stent-like
initial results (22.5% vs. 31.5%, p 5 0.003). No differences
were seen in the rates of death and MI. Espinola-Klein et al.
(80) reported lower rates of repeat revascularization and
trends toward reduced death and MI in patients with
stent-like results. The EPISTENT study randomized 2,399
patients to one of three arms: stenting with placebo,
stenting with abciximab or PTCA with abciximab (77). In
the PTCA group, provisional or bailout stenting was per-
formed for suboptimal results. Although criteria were sug-
gested for stent implantation (e.g., reduced flow, long
dissection, .70% residual diameter stenosis), this was
largely left to the discretion of the physicians. Stenting was
performed in 154 (19%) of the 796 patients in the PTCA
group. Compared with patients randomized to elective
stenting plus abciximab, the patients in the PTCA group
had higher rates of TLR (15.4% vs. 8.7%, p , 0.001) and
death (1.8% vs. 0.5%, p 5 0.02) at six months (21). In
elderly women, however, event rates were higher with
elective stenting (81).
The Optimal PTCA versus Primary Stent strategy
(OPUS) study was the first randomized trial of provisional
stenting (based on final diameter stenosis) as compared with
elective stenting. The study included short lesions
(#20 mm) in arteries $3.0 mm in diameter and excluded
more complex lesions such as angulated, calcified or ostial
lesions. In addition, patients were excluded if a multivessel
intervention was planned or if they had an MI within the
previous 24 h. For patients randomized to provisional
stenting, stents were used if the final diameter stenosis was
.20% by visual estimation (or .30% by on-line QCA) or
if the intervention was complicated by abrupt closure or
sustained or flow-limiting dissection. Stents were implanted
in 99% of the elective stent group and in 37% of the
provisional stent group. In a preliminary analysis (78), the
primary composite end point of death, MI or TLR occurred
more often in the provisional stent group than in the elective
stent group (14.9% vs. 6.1%, p 5 0.003). Most of the
difference was due to a significantly higher rate of TLR with
provisional stenting (10.1% vs. 3.0%, p , 0.005). The costs
at six months were similar between the groups, owing to
more readmissions in the provisional stent group. The
OPUS results suggest that elective stenting leads to im-
proved clinical outcomes at six months as compared with
provisional stenting, according to angiography alone. Of
note, 63% of patients assigned to the optimal PTCA/
provisional stenting strategy achieved the criteria for stent-
like results, which is higher than the incidence of stent-like
results observed in previous studies (74–76,79,80). The less
frequent use of stents in OPUS may therefore partly account
for the discrepant findings, compared with previous studies.
Visual estimation may be too imprecise to discriminate
optimal angioplasty results from those that indicate stent-
ing. Alternatively, angiographic criteria may need to be
combined with other assessment techniques.
IVUS-guided strategies. Coronary angiography may over-
estimate postprocedural lumen size, when extravasation of
contrast agent into the fractured atheromatous plaque re-
Table 5. Stent-like Results Versus Elective Stenting
Study Criteria for SLR
Patients With
SLR, n/N (%)
Restenosis
Target Lesion
Revascularization
SLR Stent SLR Stent
BENESTENT (74) Diameter stenosis #30% by QCA* 90/255 (35%) 16% 22% 20% 20%
REST (75) Diameter stenosis #30% by QCA† 98/180 (54%) NA NA 12% 11%
TOSCA (76) Diameter stenosis #35% by QCA 74/196 (38%) 55% 55% 8% 8%
EPISTENT (21,77) Operator discretion 642/796 (81%) NA NA 15%‡ 9%
OPUS (79) Diameter stenosis #30% by QCA* or #20%
by visual assessment
157/249 (63%) NA NA 10%‡ 3%
NHLBI Registry (79) Diameter stenosis #10% by visual assessment 225/1989 (11%) NA — 23%§\ —
Espinola-Klein et al. (80) Diameter stenosis #25% 246/417 (59%) NA — 35%\ —
*No major dissection. †No dissection/thrombus. ‡Includes patients who received stents for suboptimal results. §Percentage of lesions, not patients. \Ten-year follow-up.
NHLBI 5 National Heart, Lung and Blood Institute; OPUS 5 Optimal PTCA versus primary Stent strategy; QCA 5 quantitative coronary angiography; SLR 5 stent-like
results; other abbreviations as in Table 1.
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sults in hazy angiographic images. In addition, when the
angiographically normal reference segment is diffusely nar-
rowed, the vessel size may be underestimated. Intravascular
ultrasound enables visualization of the vessel wall and lumen
and more accurately displays the extent of atherosclerotic
involvement and effects of interventions on the vessel wall.
It was therefore anticipated that IVUS would be more
predictive of restenosis than angiography, but studies to date
have provided conflicting results (63,64,65,82). Use of
IVUS to guide balloon size may allow the safe use of larger
balloons to achieve larger final lumens (83). Several studies
have been performed to assess whether PTCA guided by
IVUS yields clinical outcomes comparable with those of
stenting (Table 6) (84–86). A recent single-center, nonran-
domized study reported outcomes of 144 selected patients
undergoing IVUS-guided PTCA (84). The balloon size was
based on IVUS measurements of the external elastic mem-
brane at the lesion site. Although there was a high rate of
dissection, none of the dissections led to abrupt closure or
required stenting. At one year, the rates of angiographic
restenosis and repeat revascularization were 21% and 9%,
respectively. Two other centers have reported series of
IVUS-guided PTCA with provisional stenting (85,86).
Criteria for “crossing over” to stenting included a cross-
sectional lumen area that was ,70% of the reference lumen
area, or ,5.5 mm2, or lumen-compromising dissections.
Stenting was required in about half of the patients. The
rates of restenosis and TLR were low as compared with
those in historic control subjects. Although these prelimi-
nary reports support the use of IVUS to guide balloon sizing
and provisional stenting, the optimal criteria for crossing
over to stenting have not been determined (87). To date,
there have been no direct comparisons of IVUS-guided
provisional stenting with elective stenting, although ran-
domized trials are in progress. The Gradual Inflation at
optimal Pressure vs. Stent Implantation (GIPSI) trial is
comparing IVUS-guided, prolonged balloon inflations with
a perfusion balloon catheter versus stent implantation. It
remains to be seen whether IVUS provides an incremental
benefit over angiography for provisional stenting, or
whether the benefit outweighs the additional cost of IVUS
equipment.
Coronary flow reserve: pressure gradients. As opposed to
QCA and IVUS, which assess the structural outcome of
percutaneous interventions, coronary flow reserve provides a
means to assess the functional significance of residual
stenosis. Coronary flow velocity reserve (CVR) is the ratio
of maximal hyperemic to basal flow velocities. The distal
CVR has been used as a physiologic measure of coronary
stenosis severity and correlates well with myocardial perfu-
sion imaging (88). The advent of the Doppler guide wire
has permitted continuous assessment of blood flow velocity
during percutaneous interventions. Although CVR im-
proves in most patients after angioplasty, it does not always
normalize, most likely because of residual stenosis (89). The
Doppler Endpoints Balloon Angioplasty Trial Europe
(DEBATE) correlated angiographic and Doppler end
points after PTCA with clinical outcomes in 297 patients
(65). The postprocedural CVR was most useful in predict-
ing recurrence of symptoms. However, 45% of patients with
recurrent symptoms did not have angiographic restenosis,
and stenting would not be expected to alter their outcomes.
Patients with a residual diameter stenosis #35% and distal
CVR .2.5 after PTCA had the lowest rates of restenosis,
repeat intervention and recurrent symptoms. The combined
angiographic and Doppler criteria have been tested prospec-
tively in five randomized studies (Table 7) (65,90–92).
These trials were similarly designed, such that patients
undergoing PTCA were randomly allocated to a elective
stenting strategy or to PTCA guided by Doppler and QCA.
In the DEBATE-2 study, patients in the guided angio-
plasty group were subrandomized to either stop the proce-
dure or go on to stenting. In the other trials, stenting was
performed only if the criteria for optimal results were not
Table 6. Studies Using Intravascular Ultrasound Criteria
Study IVUS Criteria of Success
Stented
Lesions
n/n (%)
TLR, Nonstented
Lesions
n/n (%)
Haase et al. (84) CSA gain $20% and/or nonocclusive dissection 0/152 (0%) 13/152 (9%)
Abizaid et al. (85) CSA $65% and no dissection 150/284 (53%) 11/134 (8.0%)
Yasukawa et al. (86) CSA .70% and no dissection 26/60 (42%) NA
CSA 5 cross-sectional area of lumen relative to reference lumen area; NA 5 not available; TLR 5 target lesion revascularization; IVUS 5 intravascular ultrasound.
Table 7. Studies Using Coronary Doppler Criteria
Study n Criteria for Optimal Result SLR, n/n (%) End Points TLR
DEBATE (65) 297 CVR .2.5 and final diameter stenosis #35% 44/202 (22%) Symptoms, restenosis, TLR 16%
DEBATE-2 (90) 616 CVR .2.5 and final diameter stenosis #35% 249/519 (48%) MACE at 12 months NA
DESTINI (91) 700 CVR .2.0 and final diameter stenosis #35% (43%) MACE at 6 months 14%
FROST (92) 251 CVR $2.2 and final diameter stenosis #35% 65/126 (52%) MLD at 6 months 15%
CRUSADE 200 CVR $2.0 or final diameter stenosis #35% NA MACE, restenosis at 6 months NA
CRUSADE 5 Coronary Revascularization UltraSound Angioplasty DEvice trial; CVR 5 coronary flow velocity reserve; DEBATE 5 Doppler Endpoints Balloon Angioplasty
Trial Europe; DESTINI 5 Dopper Endpoints STenting INternational Investigation; FROST 5 French Optimal Stenting Trial; MACE 5 major adverse clinical event;
MLD 5 minimal lumen diameter; NA 5 not available; SLR 5 stent-like result; TLR 5 target lesion revascularization.
1147JACC Vol. 36, No. 4, 2000 Cantor et al.
October 2000:1142–51 Strategies for Provisional Stenting
achieved; otherwise, the procedure was stopped. Preliminary
results have been presented for three of these studies
(90–92). Surprisingly, the proportion of patients meeting
the combined Doppler and angiographic criteria was signif-
icantly greater than that seen in DEBATE, ranging from
43% to 52%. The FRench Optimal Stenting Trial
(FROST) evaluated angiographic end points at six months
and found no difference in restenosis or MLD. The clinical
outcomes at six months did not differ significantly for
elective stenting and guided angioplasty in any of the trials.
However, the DEBATE-2 guided PTCA group subran-
domized to receive a stent had better outcomes than the
group randomized to stop after PTCA; the six-month rates
of major adverse cardiac events were 1% with stenting and
11% without stenting (p , 0.05). The FROST and Doppler
Endpoint STenting INternational Investigation coronary
flow reserve (DESTINI) results indicate that compared
with elective stenting, provisional stenting based on CFR
and angiographic criteria can avoid the costs and complica-
tions of stenting in ;50% of patients, with no compromise
in clinical or angiographic outcomes. Preliminary findings
from a cost analysis of DESTINI revealed significantly
lower in-hospital and six-month follow-up costs with the
provisional stenting strategy (93). The DEBATE-2 findings
suggest that although patients with optimal PTCA results have
low rates of adverse events, stenting in these patients leads to a
further reduction of events. The explanation that has been put
forth is that optimal PTCA may in fact be the ideal substrate
for optimal stenting. The final data from these trials, including
subgroup analyses, will be needed before making any definitive
conclusions about provisional stenting using the combination
of angiographic and Doppler results.
The pressure-derived myocardial fractional flow reserve
(FFR), a new index of coronary flow reserve, has also been
used to assess the functional significance of coronary steno-
ses. As measured by a pressure sensor mounted on a
0.014-in. guide wire, the pressure distal to the stenosis
during maximal hyperemia (Pd) is divided by the aortic
pressure (Pa). Values ,0.75 are considered hemodynami-
cally significant and have been correlated with myocardial
perfusion imaging and exercise-induced ischemia. The ad-
vantage of FFR is that it is less sensitive to hemodynamic
changes as compared with CVR (94). Bech et al. (68)
recently analyzed the prognostic utility of FFR and QCA in
60 consecutive patients undergoing angioplasty. The two-
year event-free survival rate for patients with postprocedural
residual diameter stenosis #35% and a FFR $0.90 was
significantly better than that for patients with suboptimal
values of either of these variables (88% vs. 59%, p 5 0.014).
No randomized trials of provisional stenting guided by FFR
have been performed to date.
Conclusions. Coronary stents have revolutionized percu-
taneous coronary interventions; however, like many new
technologies, initial enthusiasm has led to a very high use of
stents. Stents provide superior angiographic results and
more predictable short-term outcomes. Although random-
ized trials of stenting have shown lower restenosis rates,
caution must be exercised when extrapolating trial results to
clinical practice (95). As in thrombolytic trials (96), stent
trials generally have enrolled patients with more favorable
clinical and angiographic characteristics, leading to better
outcomes than those in patients commonly treated in
clinical practice (3,31–34).
Given the accumulating evidence supporting the feasibility
of provisional stenting strategies, it may be difficult to justify
routine stent implantation if similar clinical outcomes may be
obtained with a provisional stenting strategy. In view of the
potential for cost savings and prevention of diffuse in-stent
restenosis, priority must be given to the development of an
evidence-based optimal stenting strategy. Unresolved issues
include: 1) what is the best means to identify patients who do
not require stenting? and 2) what is the most appropriate rate
of stent use in typical clinical practice?
The OPUS results indicate that angiography alone may
be too insensitive a tool to identify patients requiring
stenting. Incorporation of baseline clinical and angiographic
data may further refine the discriminatory power of angiog-
raphy. Intravascular ultrasound, coronary Doppler imaging
and FFR may be used to provide additional prognostic
information. However, these techniques prolong procedure
times, and the additional equipment costs may offset any
potential cost savings. Patients with excellent angiographic
results after angioplasty appear to be a heterogeneous group.
Further research is needed to determine which clinical,
angiographic, IVUS or physiologic variables are most useful
and cost-effective in predicting event-free survival for pa-
tients with excellent angiographic results. It would appear
from the OPUS and EPISTENT results that provisional
stenting strategies in which ,40% of patients undergo
stenting are unlikely to result in long-term outcomes equiv-
alent to elective stenting. In the Canadian data base study,
the rates of target vessel revascularization declined over a
three-year period as the rates of stent implantation increased
from 14% to 59% (25). Although the optimal threshold for
stent use remains to be determined, the evidence to date
supports the use of stents in the majority of patients.
Nevertheless, with over 500,000 stent procedures performed
each year (59), a strategy that could prevent unnecessary
stent implantation in even a small proportion of patients
could have a large impact on health care costs while
retaining the ability to use stents for the patients most likely
to derive clinical benefit.
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